Patent intelligence · US
US 10821074
Sublingual and buccal film compositions
Sublingual and buccal film compositions
Patent details — US 10821074
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 3, 2020
- Expiration
- Oct 29, 2040
- Applicant
- Aquestive Therapeutics, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/485, A61K47/10, A61K47/12
Quick answer
US 10821074 (Sublingual and buccal film compositions) is held by Aquestive Therapeutics, Inc.. Status: granted. Granted Nov 3, 2020. Expires Oct 29, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aquestive Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/485, A61K47/10, A61K47/12, A61K9/0056, A61K9/006
More from Aquestive Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427121
Enhanced delivery epinephrine compositions
granted -
US 12403090
Oral film compositions and dosage forms having precise active dissolution profiles
granted -
US 12290597
Oral film compositions and dosage forms having precise active dissolution profiles
granted -
US 12023309
Enhanced delivery epinephrine compositions
granted -
US 11541002
Oral film compositions and dosage forms having precise active dissolution profiles
granted -
US 11273131
Pharmaceutical compositions with enhanced permeation
granted -
US 11191737
Enhanced delivery epinephrine compositions
granted -
US 11129799
Dual lane coating
granted
Frequently asked questions
What is US patent 10821074?
US 10821074 (Sublingual and buccal film compositions) is held by Aquestive Therapeutics, Inc.. Status: granted. Granted Nov 3, 2020. Expires Oct 29, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10821074?
Aquestive Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 10821074 expire?
Our index shows an expiration date of Oct 29, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.